Pharmaceutical CDMO Market Size
The pharmaceutical contract development and manufacturing organization (CDMO) market was valued at USD 173.7 billion in 2025 and is projected to reach USD 342 billion by 2035, expanding at a CAGR of 7.1% from 2026 to 2035, according to the latest report published by Global Market Insights Inc.
Pharmaceutical CDMO Market Key Takeaways
Share
2025 Market Size
$ 173.7 Billion
2026 Market Size
$ 184.9 Billion
2035 Forecast Market Size
$ 342 Billion
Regional Dominance
Largest Market
North America
Fastest Growing Region
Asia Pacific
Key Players
Market Leader: Lonza Group led with over 12% market share in 2025.
Leading Players: Top 5 players in this market include Lonza Group, Thermo Fisher Scientific, Catalent, Samsung Biologics, WuXi Biologics, which collectively held a market share of 30% in 2025.
Get Market Insights & Growth Opportunities
Download Free PDF
Market value reflects outsourced work across active pharmaceutical ingredient (API) development and production, finished drug formulation, clinical and commercial manufacturing, packaging and labeling, regulatory support, and related technical services. The market excludes a sponsor’s captive manufacturing revenue where no external contract-development or manufacturing service is purchased. Growth rests on a change in operating model: drug sponsors increasingly retain portfolio strategy and commercial ownership while specialist manufacturers absorb process development, scale-up, quality-system execution, and commercial supply obligations.
The market reaches USD 184.9 billion in 2026. Growth through 2035 combines higher program volume with a richer mix of biologics, high-potency APIs (HPAPIs), antibody-drug conjugates (ADCs), and advanced therapies, all of which demand specialized containment, bioprocessing, or sterile fill-finish capability. The sizing approach triangulates service revenues across development, manufacturing, and supporting services, then tests segment and regional allocation against the 2025 market total. Forecasts assess outsourcing penetration, development-pipeline depth, modality mix, capacity constraints, and regulatory operating requirements; driver and restraint effects are directional rather than strictly additive.
GMI Analyst View
The sector will expand most reliably where technical complexity creates a durable reason to outsource rather than a temporary shortage of internal capacity. Commercial manufacturing remains the largest service pool, but development work increasingly determines who captures later-stage supply agreements because process knowledge and validation history travel with the program. By 2028, the separation between commodity oral-solid manufacturing and specialized biologics, HPAPI, and advanced-therapy production will be more consequential than headline capacity additions. This shift raises the value of integrated development-to-commercial platforms and regulatory execution across multiple sites.
Key Drivers
Driver
Approx. CAGR Impact
Impact
Timeline
Increasing outsourcing by pharmaceutical and biotech companies
+2.3-3.2%
Global – strongest across development-to-commercial programs
Short term (≤2 years)
Growing biologics and advanced therapy pipeline
+1.8-2.6%
North America, Europe, and Asia Pacific – concentrated in specialized manufacturing
Medium term (2-4 years)
Capacity constraints and specialized infrastructure needs
+1.5-2.2%
North America and Europe – acute in sterile fill-finish, viral vectors, and HPAPI
Short term (≤2 years)
Rising R&D investment and drug approvals globally
+1.3-2.0%
Global – driven by clinical-to-commercial progression
Medium term (2-4 years)
Get Market Insights & Growth Opportunities
Download Free PDF
Increasing outsourcing by pharmaceutical and biotech companies. Outsourcing has become an operating decision rather than a residual-capacity solution. FDA approval analysis cited in the source package places outsourced API manufacturing in 73% of novel drug approvals in 2025, versus an 11-year average of 61%; finished-dose outsourcing reached 65%, above its long-run 50% average. Pharma Manufacturing [1]Pharma Manufacturing, “Pharma Manufacturing” – pharmamanufacturing.com Sponsors use CDMOs to avoid fixed investment in GMP assets, specialized labor, validation systems, and multi-market quality operations. Smaller innovators carry the strongest structural dependence because they typically lack commercial manufacturing infrastructure. The commercial effect is durable baseline demand for integrated process development and supply programs.
Growing biologics and advanced therapy pipeline. The global development pipeline reached 22,825 molecules in 2024, up 7.2% from the prior year. IQVIA Institute for Human Data Science [2]IQVIA Institute for Human Data Science, “IQVIA Institute for Human Data Science” – iqvia.com Biologics accounted for 45% of FDA novel drug approvals in 2025, while the European Medicines Agency recommended 104 medicines, including 41 biosimilars. European Medicines Agency [3]European Medicines Agency, “European Medicines Agency” – ema.europa.eu Mammalian cell culture, viral clearance, cold-chain execution, and sterile fill-finish requirements move these programs toward specialist partners. The resulting demand is not evenly distributed: facilities with proven large-molecule and injectable capability command the most strategic place in sponsor qualification plans.
Capacity constraints and specialized infrastructure needs. Sterile fill-finish, viral-vector suites, and HPAPI capacity remain difficult to replicate because equipment alone does not establish a qualified production system. BioPlan data indicates that 82.6% of cell and gene therapy facilities outsource at least part of manufacturing activity, while mammalian and microbial fermentation outsourcing exceeds 77%. BioPlan Associates [4]BioPlan Associates, “BioPlan Associates” – bioplanassociates.com These constraints lengthen qualification cycles and shift sponsor attention toward available, validated capacity. Capacity scarcity therefore improves the economics of specialist services while limiting how quickly supply can respond.
Rising R&D investment and drug approvals globally. Large pharmaceutical-company R&D expenditure reached USD 190 billion in 2024, a 73% increase over five years, and biopharma funding reached USD 102 billion. IQVIA Institute for Human Data Science PhRMA member companies invested USD 104.3 billion in R&D in 2024. PhRMA [5]Pharmaceutical Research and Manufacturers of America, “PhRMA” – phrma.org The immediate effect is more development work; the later effect is a larger cohort of programs requiring scale-up, validation, and commercial supply. That progression ties CDMO demand to the quality and complexity of the pipeline, not simply the number of molecules.
Key Restraints
Restraint
Approx. CAGR Impact
Impact
Timeline
Regulatory complexity and compliance burden
-0.9-1.4%
Global – concentrated in multi-site and cross-jurisdiction programs
Short term (≤2 years)
Pricing pressure and competition
-0.8-1.2%
Global – strongest in commodity APIs and solid-dose manufacturing
Short term (≤2 years)
Regulatory complexity and compliance burden. CDMOs working across jurisdictions must maintain current Good Manufacturing Practice (cGMP) compliance while satisfying FDA, EMA, International Council for Harmonisation (ICH), and country-specific expectations. Quality-system maintenance, data integrity, traceability, inspection readiness, and site-change control impose recurring cost and management requirements. The constraint is most material for operators managing shared facilities and multiple client programs. Investment in enterprise quality systems, dedicated regulatory functions, and segregated high-risk capacity can mitigate the burden, but it cannot eliminate the qualification time required before a facility supports commercial supply.
Pricing pressure and competition. Standard small-molecule APIs and oral solid-dose products face aggressive cost competition, particularly where Asian manufacturing capacity offers scale advantages. This pressure compresses margins and makes service breadth, reliability, and regulatory history more important differentiators. By contrast, biologics drug product, HPAPI, and cell and gene therapy work retain higher barriers because sponsors prioritize technical performance and validated capacity. The market consequently divides into a cost-led commodity tier and a capability-led specialist tier.
Market Opportunities
Expansion of cell and gene therapy, mRNA, and ADC production creates opportunity where CDMOs can deliver validated bioconjugation, viral-vector, sterile fill-finish, or lipid nanoparticle capabilities. Long-term outsourcing contracts also favor providers that retain process knowledge from development through commercial supply. Reshoring and supply-chain diversification add another route to demand in North America, Europe, and India, where sponsors seek resilient alternatives to concentrated manufacturing networks.
GMI Analyst View
Outsourcing growth will remain resilient even if conventional small-molecule pricing stays under pressure because the strongest demand drivers arise from organizational and technical constraints. Biologics and advanced modalities raise the cost of internalizing manufacturing, while sponsor vendor consolidation rewards platforms that reduce technology-transfer exposure. The second-order effect is a wider performance gap between CDMOs that sell isolated capacity and those that hold process, quality, packaging, and regulatory capabilities within one program architecture. Through 2030, service integration will be a more reliable source of share gain than price competition.
Pharmaceutical CDMO Market Segment Analysis
By Service
Contract development. Contract development represented 23.1% of 2025 revenue and covers formulation development, process development, analytical method development, and clinical manufacturing. The segment creates the technical file and manufacturing know-how that later support commercial transfer. More than 22,800 molecules were in clinical development in 2024, and funding at a 10-year high supports the flow of early-stage engagements. IQVIA Institute for Human Data Science Integrated CMC platforms at Almac Group and Abzena illustrate why sponsors value a continuous route from development into later manufacturing. By 2030, providers that can retain development programs through scale-up will capture a larger share of downstream commercial value.
To get key market trends
Download Free PDF
Contract manufacturing. Contract manufacturing accounted for 48.7% of 2025 revenue and remains the central commercial service category. The segment includes long-term API and drug-product supply under approved manufacturing and quality systems. Outsourced API work featured in 73% of novel FDA approvals in 2025, confirming how deeply contract production is embedded in the commercial model. Pharma Manufacturing Lonza, Thermo Fisher Scientific’s Patheon business, and Samsung Biologics demonstrate the capital and regulatory depth required for commercial-scale work. The segment will retain scale leadership through 2035, although mix will shift toward technically complex modalities.
Packaging and labeling. Packaging and labeling contributed 12.4% of 2025 revenue. Work includes primary and secondary packaging, serialization, clinical-trial packaging, vials, prefilled syringes, and combination drug-device assembly. PCI Pharma Services committed more than USD 365 million across US and EU facilities in 2024, including advanced drug delivery and combination assembly capacity in Rockford, Illinois. The service category benefits when biologics move from clinic to commercial supply because presentation, traceability, and device integration become part of the delivery system. By 2028, differentiated packaging will carry greater weight in sponsor selection for injectable and patient-administered products.
Regulatory support and quality services. Regulatory support and quality services represented 9.8% of revenue. They cover CMC documentation, submission support, GMP system management, agency interactions, and post-approval change management. The 2025 approval flow of 46 FDA novel drugs and 104 EMA-recommended medicines expands the base of programs requiring controlled lifecycle management. U.S. Food and Drug Administration [6]U.S. Food and Drug Administration, “U.S. Food and Drug Administration” – fda.gov European Medicines Agency This work is difficult to unbundle from manufacturing once a sponsor has qualified a site. Regulatory capability will remain a central retention mechanism for multi-product and multi-market accounts.
Other services. Other services accounted for 6.0% of 2025 revenue, including technology transfer, logistics, process optimization, and clinical-trial support. Technology transfer is commercially sensitive because a change in site or process can create validation and supply-continuity risk. CDMOs with platform-aligned manufacturing and experienced transfer teams can reduce that risk for sponsors. This category becomes more valuable as procurement shifts from discrete transactions toward multi-year operational partnerships.
By Product
API. APIs represented 40.9% of 2025 pharmaceutical CDMO revenue. Chemical APIs accounted for 51.7% of API revenue, biological APIs for 31.6%, and HPAPIs for 16.7%. Chemical API demand remains anchored in large small-molecule supply programs, while biologic APIs require upstream cell culture and downstream purification capability. Lonza’s HPAPI operations in Visp and Cambrex’s Charles City expansion show the containment and scale investment demanded by potent compounds. The product mix will move toward biological and potent APIs through 2030 as ADC and biologics programs progress.
Finished drug formulations. Finished drug formulations held 59.1% of 2025 revenue. Solid-dose products accounted for 45.8% of FDF revenue, liquid-dose products for 28.6%, semi-solid products for 15.4%, and other dosage forms for 10.2%. Solid doses provide volume stability, while liquid biologics, lyophilized vials, prefilled syringes, autoinjectors, and inhaled products create higher-complexity work. Catalent’s Bloomington biologics fill-finish site and PCI Pharma’s investment in drug-device assembly show where the most differentiated FDF capacity is being built. By 2035, value growth will outpace volume growth in injectable and combination-product formats.
By Drug Type
Small molecules. Small molecules accounted for 62.1% of 2025 revenue. Their commercial base includes branded and generic oral solids, controlled substances, potent compounds, synthetic peptides, and oligonucleotides. Small-molecule API outsourcing reached 89% among FDA novel drug approvals in 2025. Pharma Manufacturing Cambrex and SK pharmteco illustrate demand for peptide, controlled-substance, and HPAPI infrastructure. The segment will remain the market’s revenue foundation, though price pressure will favor operators with specialized chemistries, regulatory depth, and reliable scale.
Large molecules. Large molecules represented 37.9% of 2025 revenue and include monoclonal antibodies, biosimilars, ADCs, cell therapies, gene therapies, mRNA medicines, and viral-vector products. Samsung Biologics operates more than 600,000 liters of cumulative bioreactor capacity in Songdo, while Fujifilm Diosynth Biotechnologies is expanding Hillerød toward 12 × 20,000-liter bioreactors. Outsourcing is particularly high in advanced therapy, where 82.6% of facilities outsource some manufacturing activity. BioPlan Associates Large-molecule revenue will gain mix share through the forecast period because qualified capability remains scarce.
By Therapeutic Area
Oncology. Oncology led the market with 27.6% of 2025 revenue. Its modality mix spans cytotoxic small molecules, targeted biologics, monoclonal antibodies, bispecific antibodies, ADCs, CAR-T therapies, and radiopharmaceuticals. Abzena’s bioconjugation and sterile fill-finish capabilities, alongside Piramal Pharma Solutions’ Lexington investment for sterile injectables and ADCs, show how oncology programs translate into specialized capacity demand. The category will retain leadership through 2035 because it combines a deep pipeline with high manufacturing complexity.
Metabolic and endocrine. Metabolic and endocrine disorders accounted for 16.4% of revenue. GLP-1 receptor agonist programs have increased demand for peptide API synthesis and injectable drug product manufacturing, while insulin analogues and biosimilar insulin require sterile fill-finish and cold-chain execution. SK pharmteco’s planned Sejong facility and CordenPharma’s peptide operations address this operating requirement. Larger indications and additional geographic launches will support above-average manufacturing demand through the late 2020s.
Cardiovascular. Cardiovascular products represented 14.3% of revenue. The established base remains centered on oral small-molecule medicines, but PCSK9 inhibitors, antisense oligonucleotides, and investigational gene therapies introduce more complex manufacturing requirements. The shift matters because it changes the service mix from high-volume solid-dose supply toward biologic, oligonucleotide, and HPAPI capability. By 2030, these newer modalities will increase revenue per program even where patient volumes remain more limited.
CNS and psychiatry. CNS and psychiatry accounted for 10.1% of revenue. The category includes small molecules, peptides, and emerging biologics for depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease, and rare neurologic conditions. Controlled-substance manufacturing is commercially important because it requires specialized licensed capacity, containment, and inventory controls. Cambrex’s controlled-substance and HPAPI capabilities indicate the kind of combined regulatory and technical profile that supports complex CNS outsourcing. The segment will continue to reward operators able to manage specialty requirements rather than generic capacity alone.
Infectious diseases and vaccines. Infectious diseases and vaccines represented 22.1% of revenue. Manufacturing requirements include vaccine drug substance, adjuvant handling, lyophilization, and high-volume fill-finish. Fujifilm Diosynth Biotechnologies and CordenPharma maintain capabilities relevant to this supply category. EMA recommendations in 2025 included a respiratory syncytial virus prevention medicine, adding to the commercial and preparedness-driven demand base. European Medicines Agency Through 2030, surge-capable capacity and specialized fill-finish will remain strategically valuable.
Other therapeutic areas. Other therapeutic areas accounted for 9.5% of revenue across immunology, respiratory, gastrointestinal, rare diseases, dermatology, ophthalmology, and women’s health. Rare-disease programs often require small batches, specialized formulations, and intensive analytical control. The EMA recommended 16 rare-disease medicines in 2025, including a first gene therapy for dystrophic epidermolysis bullosa. European Medicines Agency Almac Group and Recipharm address portions of this specialty production profile through formulation, packaging, inhalation, and injectable services.
By End Use
Pharmaceutical companies. Pharmaceutical companies held 56.5% of 2025 revenue. Large innovators use CDMOs for long-term supply, capacity flexibility, and backup manufacturing; generic manufacturers rely on competitive API and oral-solid networks. PhRMA member R&D investment of USD 104.3 billion in 2024 supports the flow of programs entering commercial supply. PhRMA This buyer group will continue to consolidate suppliers around reliability, regulatory performance, and service breadth.
Biotechnology companies. Biotechnology companies accounted for 35.9% of revenue and constitute the most dynamic buyer group. Many lack the capital base to build and operate GMP facilities, making them dependent on external process development, clinical supply, and commercial manufacturing. Funding reached USD 102 billion in 2024, supporting biotechnology formation and development-stage demand. IQVIA Institute for Human Data Science As biologic programs mature, development agreements can convert into larger commercial supply contracts without changing the customer category.
Other end users. Other end users accounted for 7.6% of revenue, including virtual pharma companies, academic institutions, government organizations, contract research organizations, animal-health companies, and specialty pharmaceutical firms. These buyers tend to need targeted development, clinical manufacturing, or specialty supply rather than broad internal capacity substitution. Their demand reinforces the value of flexible, integrated platforms that can support small batches and regulatory qualification.
GMI Analyst View
Segment economics increasingly turn on whether a CDMO participates before commercial scale-up. Development entry gives a provider process familiarity, analytical history, and a practical advantage when sponsors select later manufacturing capacity. That dynamic links contract development, regulatory services, and contract manufacturing rather than leaving them as independent revenue pools. Through 2030, the most valuable portfolios will pair small-molecule volume with large-molecule, HPAPI, or complex drug-product capability that protects pricing and client retention.
Pharmaceutical CDMO Market Regional Analysis
North America
North America held 39.1% of 2025 global revenue, supported by a dense concentration of pharmaceutical and biotechnology innovators, FDA approval activity, and established CDMO infrastructure across New Jersey, North Carolina, Massachusetts, and California. The FDA approved 46 novel drugs in 2025. U.S. Food and Drug Administration In October 2025, Cambrex announced a USD 120 million Charles City, Iowa expansion that adds 40% large-scale API and peptide capacity. Piramal Pharma Solutions broke ground in June 2025 on a USD 90 million expansion targeting sterile injectables and ADC therapies at Lexington, Kentucky. Canada contributes sterile-biologics and small-molecule capacity to North American supply networks. The principal regional constraint is the time and cost required to commission GMP-compliant capacity.
Learn more about the key segments shaping this market
Download Free PDF
Europe
Europe accounted for 28.7% of 2025 revenue, with Germany, Switzerland, France, the UK, and Ireland acting as key manufacturing hubs. Switzerland concentrates HPAPI and biologics API expertise through sites such as Lonza’s Visp operations and Siegfried’s Zofingen facility. WuXi Biologics’ Dundalk, Ireland facility received its first EMA approval for commercial manufacturing of an innovative biologic in August 2025. The EMA recommended 41 biosimilars in 2025, creating demand for approved European manufacturing locations. European Medicines Agency In the UK, SEKISUI Diagnostics completed a £15.7 million cGMP microbial-fermentation capacity expansion in November 2024. Post-Brexit divergence adds compliance work for suppliers serving both the UK and EU.
Asia Pacific
Asia Pacific accounted for 25.6% of 2025 revenue and is the fastest-growing region. China maintains scale in small-molecule API and biologics drug-substance manufacturing; WuXi Biologics began construction of a Chengdu microbial-manufacturing site in May 2025, with a 15,000-liter fermenter and potential expansion to 60,000 liters. India benefits from supply-chain diversification, with Syngene International and Piramal Pharma Solutions expanding relevant capability. South Korea is scaling biologics and peptide capacity, with Samsung Biologics targeting 20-25% annual revenue growth in 2025 and SK pharmteco announcing a USD 260 million Sejong investment in September 2024. Japan and Australia remain part of the regional demand and supply base, although the approved evidence package does not quantify country-specific values. Asia Pacific’s advantage is its breadth of cost, scale, and technology options; its constraint is uneven regulatory and commercial positioning across countries.
Latin America and Middle East & Africa
Brazil, Mexico, Argentina, Saudi Arabia, South Africa, and the UAE are included in the geographic scope. The approved evidence package does not supply country-level market values, facility actions, or policy detail for these markets. Their coverage remains qualitative to avoid inferring unsupported country economics. These regions are relevant to commercial supply, localization, and future demand access, but no quantified regional allocation is asserted.
GMI Analyst View
Regional competition will not converge on one manufacturing model. North America gains from sponsor proximity and reshoring demand, Europe from mature regulatory credibility and complex-modality infrastructure, and Asia Pacific from scale, cost, and rapidly expanding biologics capacity. Supply-chain diversification will favor multi-region networks through 2030 because sponsors seek continuity alongside cost efficiency. The practical implication is that regional footprint matters most when it connects qualified capacity, regulatory acceptance, and program-transfer capability.
Pharmaceutical CDMO Market Share & Competitive Landscape
The market is moderately fragmented. Lonza Group holds the leading individual position at approximately 12% of 2025 global revenue, while Lonza, Thermo Fisher Scientific (Patheon), Catalent, Samsung Biologics, and WuXi Biologics collectively hold approximately 30%. The remaining 70% is distributed across regional, modality-focused, and service-specialist providers. This structure leaves room for specialized competitors but raises the value of integrated platforms that can absorb complex work across development, production, packaging, and quality operations.
Lonza competes through integrated small-molecule, biologics, cell and gene therapy, HPAPI, and capsule capability, including major biologics operations in Visp and Portsmouth. Thermo Fisher Scientific’s Patheon business combines global drug-substance and drug-product manufacturing with PharmaServices development support. Catalent supplies biologics, gene therapy, oral delivery, and consumer-health programs, including its Bloomington biologics fill-finish operation. Samsung Biologics competes from Songdo’s large-scale biologics complex and a pure-play CDMO strategy. WuXi Biologics operates a multi-site biologics network across China, Ireland, Germany, Singapore, and the US; it reported 42 regulatory inspections and 97 license approvals as of end-2024.
Competition separates along capability lines. Commodity API and standard solid-dose suppliers compete on cost, capacity availability, and location. Providers of ADCs, lipid nanoparticle formulations, HPAPIs, cell and gene therapies, and complex sterile products compete on validation history, technical execution, and regulatory quality. Expansion remains a major competitive instrument: Cambrex, Piramal Pharma Solutions, Fujifilm Diosynth Biotechnologies, PCI Pharma Services, WuXi Biologics, and SK pharmteco have all announced capacity investments in the approved evidence package.
Recent Industry Developments
Oct 2025: Cambrex announced a USD 120 million investment at Charles City, Iowa to increase API manufacturing and peptide capacity by 40%. The expansion strengthens US capacity for complex small-molecule and peptide programs.
Aug 2025: WuXi Biologics’ Dundalk facility received its first EMA approval for commercial manufacturing of an innovative biologic. The approval reinforces Ireland’s role in European biologics supply.
Jun 2025: Piramal Pharma Solutions broke ground on a USD 90 million expansion across Lexington, Kentucky, and Grangemouth, Scotland for sterile injectables and ADC therapies. Lexington batch output is projected to more than double by late 2027.
May 2025: WuXi Biologics began construction of a Chengdu commercial microbial manufacturing site with a 15,000-liter fermenter and planned drug-product capacity exceeding 10 million vials annually. The project expands China’s biologics and microbial-manufacturing footprint.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Request Sectional Pricing